Filing Details

Accession Number:
0001209191-11-017826
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-03-14 17:31:56
Reporting Period:
2011-03-10
Filing Date:
2011-03-14
Accepted Time:
2011-03-14 17:31:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1267602 Alimera Sciences Inc ALIM Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1489535 W. Calvin Roberts 6120 Windward Parkway
Suite 290
Alpharetta GA 30005
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-03-10 10,000 $7.75 20,000 No 4 P Indirect See footnote
Common Stock Acquisiton 2011-03-10 10,000 $7.75 20,200 No 4 P Indirect See footnote
Common Stock Acquisiton 2011-03-10 10,000 $7.75 20,000 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Footnotes
  1. The shares are held by The David Roberts Trust. Calvin Roberts is a Trustee of The David Roberts Trust. Calvin Roberts disclaims beneficial ownership of these securities and this report shall not be deemed an admission that he is the beneficial owner of such securities for the purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
  2. The shares are held by The Lindsay Roberts Trust. Calvin Roberts is a Trustee of The Lindsay Roberts Trust. Calvin Roberts disclaims beneficial ownership of these securities and this report shall not be deemed an admission that he is the beneficial owner of such securities for the purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
  3. The shares are held by The Joanna Roberts Trust. Calvin Roberts is a Trustee of The Joanna Roberts Trust. Calvin Roberts disclaims beneficial ownership of these securities and this report shall not be deemed an admission that he is the beneficial owner of such securities for the purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.